Which CDK4/6 Inhibitors are available?

This directory covers 3: Ibrance, Kisqali, Verzenio.

CDK4/6 Inhibitors

Also called cyclin-dependent kinase inhibitors

CDK4/6 inhibitors stall the cell cycle. By blocking cyclin-dependent kinases 4 and 6, they stop breast cancer cells from moving out of the growth phase and dividing. They are given as a daily tablet alongside hormone therapy in hormone-receptor-positive, HER2-negative advanced breast cancer, where adding them roughly doubles the time before the disease progresses.

What this class is used for

HR-positive, HER2-negative advanced or metastatic breast cancer

3 CDK4/6 Inhibitors in this directory

Ibrance

Palbociclib

An oral therapy for hormone-receptor-positive advanced breast cancer.

Kisqali

Ribociclib

An oral targeted therapy used to treat hormone receptor-positive advanced breast cancer.

Verzenio

Abemaciclib

An oral targeted therapy used to treat hormone receptor-positive breast cancer.

Compare CDK4/6 Inhibitors side by side

Ibrance VS Kisqali Ibrance VS Verzenio Kisqali VS Verzenio

Browse other drug classes

ARBs Anti-amyloid Antibodies Antibiotics Antibody-drug Conjugates Anticoagulants Anticonvulsants Antihistamines Antiplatelets Asthma & COPD Inhalers Atypical Antipsychotics BTK Inhibitors Beta Blockers CD20 Antibodies CGRP Inhibitors COVID-19 Antivirals Checkpoint Inhibitors Cholinesterase Inhibitors Complement Inhibitors DPP-4 Inhibitors EGFR Inhibitors Enzyme Replacement Therapy GLP-1 Agonists Gene & Cell Therapies HIV Antiretrovirals Hepatitis C Antivirals IL-1 Inhibitors IL-17 Inhibitors IL-23 Inhibitors IL-5 Inhibitors IL-6 Inhibitors Insulins JAK Inhibitors PARP Inhibitors PCSK9 Inhibitors Proton Pump Inhibitors SGLT2 Inhibitors SSRIs & SNRIs Statins TNF Inhibitors TTR Silencers Tyrosine Kinase Inhibitors

Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons